↓ Skip to main content

Dove Medical Press

Article Metrics

Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease

Overview of attention for article published in Therapeutics and Clinical Risk Management, May 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

twitter
4 tweeters
googleplus
1 Google+ user
video
1 video uploader

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
18 Mendeley
Title
Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease
Published in
Therapeutics and Clinical Risk Management, May 2014
DOI 10.2147/tcrm.s39216
Pubmed ID
Authors

Sergio Leonardi, Rita Camporotondo, Gaetano De Ferrari, Gianmarco Iannopollo

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 18 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 4 22%
Researcher 3 17%
Student > Doctoral Student 2 11%
Student > Ph. D. Student 1 6%
Lecturer 1 6%
Other 2 11%
Unknown 5 28%
Readers by discipline Count As %
Medicine and Dentistry 8 44%
Pharmacology, Toxicology and Pharmaceutical Science 1 6%
Agricultural and Biological Sciences 1 6%
Nursing and Health Professions 1 6%
Neuroscience 1 6%
Other 1 6%
Unknown 5 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 June 2014.
All research outputs
#1,719,101
of 8,911,167 outputs
Outputs from Therapeutics and Clinical Risk Management
#87
of 740 outputs
Outputs of similar age
#35,079
of 180,183 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#1
of 26 outputs
Altmetric has tracked 8,911,167 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 740 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 180,183 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.